ZURICH, Dec 18 () - Swiss pharma giants Novartis and Roche on Thursday backed U. efforts to lower the ​cost of drugs and are ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...

These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...

Indiana University and Eli Lilly are working together to expand clinical trials in the state. IU President Pamela Whitten and Lilly CEO David Ricks signed a $40 million, five-year deal Wednesday.

Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing ...

Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.

MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward ...

Policy swings have made it a slippery year for pharma ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...

Eli Lilly and Company has finalized its acquisition of Adverum Biotechnologies, a move that delivers a promising gene therapy ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

The race to develop safer, longer lasting, and less invasive treatments is accelerating, and at the heart of that challenge lies drug delivery. Eli Lilly’s move to acquire Adverum Biotechnologies ...